|
|
|
|
| LEADER |
04592nam a22003975i 4500 |
| 001 |
000280198 |
| 005 |
20210426100134.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100917s2010 ne | s |||| 0|eng d |
| 020 |
|
|
|a 9789048195312
|
| 024 |
7 |
|
|a 10.1007/978-90-481-9531-2
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a From Molecular to Modular Tumor Therapy :
|b Tumors are Reconstructible Communicatively Evolving Systems /
|c edited by Albrecht Reichle.
|
| 250 |
|
|
|a 1st ed. 2010.
|
| 260 |
# |
# |
|a Dordrecht :
|b Springer Netherlands :
|b Imprint: Springer,
|c 2010.
|
| 300 |
|
|
|a VIII, 568 p. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a The Tumor Microenvironment ;
|v 3
|
| 505 |
0 |
|
|a Therapy-Derived Systems Biology: A Pragmatic Communication Theory -- Bridging Theory and Therapeutic Practice: From Generalized Disease Models to Particular Patients -- Tumor Systems Need to be Rendered Usable for a New Action-Theoretical Abstraction: The Starting Point for Novel Therapeutic Options -- Principles of Modular Tumor Therapy -- Tumors Share Common Processes During Tumor Evolution: Communicative Aspects of a Situation’s Interpretation for Creating Systems-Directed Therapies -- Cancer and Coagulation; Focusing on Tissue Factor and Heparanase -- The Role of Mesenchymal Cells in Cancer: Contribution to Tumor Stroma and Tumorigenic Capacity -- Shaping Tumor Associated Macrophages: The Role of NF-?B -- The Metabolic Achilles Heel: Tumor Cell Metabolism as Therapeutic Target -- Could Be Systems-Directed Therapy Approaches Promising in Glioblastoma Patients? -- Systems-Relevant Molecular and Cellular Targets: Implementation of Modular ‘Knowledge’ -- Functional Impacts of Signal Integration: Regulation of Inflammation-Related Transcription Factors by Heterotrimeric G Proteins -- Molecular Cross-Talk Between Nuclear Receptors and Nuclear Factor-?B -- The Biomodulatory Capacities of Low-Dose Metronomic Chemotherapy: Complex Modulation of the Tumor Microenvironment -- Tumors are Evolvable Modular and Rationalized Systems: From Molecular to Modular Tumor Therapy -- Systems Biology: A Therapeutic Target for Tumor Therapy -- The Comparative Uncovering of Tumor Systems Biology by Modularly Targeting Tumor-Associated Inflammation -- Searching for the ‘Metabolism’ of Evolution -- Biomodulatory Therapy Approaches in Metastatic Cancer -- The Impact of Inflammation Control and Active Cancer Palliation on Metabolic Pathways Determining Tumor Progression and Patient Survival -- Pioglitazone and Rofecoxib Combined with Angiostatically Scheduled Capecitabine in Far-Advanced Hepatobiliary Carcinoma -- C-Reactive Protein As a Secretome-Derived Biomarker for Predicting Response to Biomodulatory Therapy in Metastatic Renal Clear Cell Carcinoma -- Modular Therapy Approach in Metastatic Castration-Resistent Prostate Cancer -- Systems-Directed Therapy in Metastatic Castration-Resistent Prostate Cancer (CRCP) -- Criteria for Checking Systems Behavior and Creating Predictions: Systems-Associated Biomarkers and Molecular Imaging -- Early Detection of Systems Response: Molecular and Functional Imaging of Angiogenesis -- Secretome Proteomics, a Novel Tool for Biomarkers Discovery and for Guiding Biomodulatory Therapy Approaches -- Cyclooxygenase 2 (COX2) and Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Are Stage-Dependent Prognostic Markers of Malignant Melanoma -- Pharmacological Considerations on Systems Biological Therapy Approaches -- Uncovering Tumor Systems Biology by Biomodulatory Therapy Strategies -- Breathing New Life into Old Drugs: Indication Discovery by Systems Directed Therapy -- Tumors’ Systems Biology: Implications for Personalized Therapy -- A Methodological Approach to Personalized Therapies in Metastatic Cancer -- Summary -- To Be an Object in a Biological System -- From Molecular to Modular, from Theme-Dependent to Evolution-Adjusted Tumor Therapy.
|
| 650 |
|
0 |
|a Oncology .
|
| 650 |
|
0 |
|a Medicinal chemistry.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Pharmaceutical technology.
|
| 650 |
|
0 |
|a Evolutionary biology.
|
| 650 |
1 |
4 |
|a Oncology.
|
| 650 |
2 |
4 |
|a Medicinal Chemistry.
|
| 650 |
2 |
4 |
|a Medicine/Public Health, general.
|
| 650 |
2 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|
| 650 |
2 |
4 |
|a Evolutionary Biology.
|
| 700 |
1 |
|
|a Reichle, Albrecht.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|